Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 529Neoplasms 475Carcinoma, Non-Small-Cell Lung 394Prostatic Neoplasms 308Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 218Ovarian Neoplasms 200Leukemia, Myeloid, Acute 199Pancreatic Neoplasms 187Multiple Myeloma 175Squamous Cell Carcinoma of Head and Neck 134Recurrence 132Stomach Neoplasms 131Brain Neoplasms 126Carcinoma, Hepatocellular 125Melanoma 124Endometrial Neoplasms 122Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Hematologic Neoplasms 100Head and Neck Neoplasms 99Lymphoma 97Carcinoma, Renal Cell 97Urinary Bladder Neoplasms 93Sarcoma 90Glioma 88Lymphoma, Non-Hodgkin 82Rectal Neoplasms 81

Interventions

fludarabine 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Select Advanced Solid Tumors × 90 days × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡